The effect of low doses of betaine on plasma homocysteine in healthy volunteers

被引:23
作者
Alfthan, G [1 ]
Tapani, K
Nissinen, K
Saarela, J
Aro, A
机构
[1] Natl Publ Hlth Inst KTL, Dept Hlth & Funct Capac, Helsinki, Finland
[2] Natl Publ Hlth Inst KTL, Dept Epidemiol & Hlth Promot, Helsinki, Finland
[3] Natl Publ Hlth Inst KTL, Dept Mol Med, Helsinki, Finland
[4] Oy Sinebrychoff Ab, Kerava, Finland
关键词
betaine; homocysteine; dose-response; folic acid;
D O I
10.1079/BJN20041253
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Homocysteine is a risk factor for vascular diseases, and lowering of plasma total homocysteine (tHcy) may be beneficial for health. Homocysteine can be remethylated to methionine by betaine-homocysteine methyltransferase using betaine (2(N,N,N-trimethyl)glycine) as methyl donor. A dose of 6 g betaine/d has been used in the treatment of homocystinuria, but data on the dose-response are scarce. Thirty-four healthy men and women were supplied with doses of 1, 3 and 6 g betaine and then with 6 g betaine + 1 mg folic acid for four consecutive 1-week periods. The mean plasma tHcy concentration decreased by 1.1 (NS), 10.0 and 14.0% (P<0.001) after supplementation with 1, 3 and 6 g betaine respectively. A further decrease in plasma tHcy by 5% (P<0.01) was achieved by combining ling folic acid with the 6 g betaine dose. Plasma betaine increased from 31 (So 13) to 255 (SD 136) mumol/l in a dose-dependent manner (R-2 0.97). We conclude that plasma tHcy is lowered rapidly and significantly by 3 or 6 g betaine/d in healthy men and women.
引用
收藏
页码:665 / 669
页数:5
相关论文
共 25 条
[1]   Folate intake, plasma folate and homocysteine status in a random Finnish population [J].
Alfthan, G ;
Laurinen, MS ;
Valsta, LM ;
Pastinen, T ;
Aro, A .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2003, 57 (01) :81-88
[2]   POLYMORPHIC DNA REGION ADJACENT TO THE 5'-END OF THE HUMAN INSULIN GENE [J].
BELL, GI ;
KARAM, JH ;
RUTTER, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (09) :5759-5763
[3]  
Brattström L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894
[4]  
Brouwer IA, 1999, AM J CLIN NUTR, V69, P99
[5]   Betaine supplementation and plasma homocysteine in healthy volunteers [J].
Brouwer, IA ;
Verhoef, P ;
Urgert, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (16) :2546-2547
[6]   Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].
Eikelboom, JW ;
Lonn, E ;
Genest, J ;
Hankey, G ;
Yusuf, S .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375
[7]   C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations [J].
Gudnason, V ;
Stansbie, D ;
Scott, J ;
Bowron, A ;
Nicaud, V ;
Humphries, S .
ATHEROSCLEROSIS, 1998, 136 (02) :347-354
[8]   Hyperhomocystinemia -: A risk factor or a consequence of coronary heart disease? [J].
Knekt, P ;
Reunanen, A ;
Alfthan, G ;
Heliövaara, M ;
Rissanen, H ;
Marniemi, J ;
Aromaa, A .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (13) :1589-1594
[9]  
Laryea MD, 1998, CLIN CHEM, V44, P1937
[10]   An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria [J].
Matthews, A ;
Johnson, TN ;
Rostami-Hodjegan, A ;
Chakrapani, A ;
Wraith, JE ;
Moat, SJ ;
Bonham, JR ;
Tucker, GT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (02) :140-146